Skip to main content
SpringerLink
Log in

Update 2016 – Immuntherapie beim Urothelkarzinom

Update 2016 – Immunotherapy for urothelial carcinoma

  • AUO
  • Published:
Der Urologe Aims and scope Submit manuscript

Zusammenfassung

Das fortgeschrittene Blasenkarzinom ist ein aggressiver Tumor mit einer schlechten Prognose. Neben der operativen Therapie spielte bisher nur die klassische Chemotherapie mit platinhaltigen Medikamenten die wichtigste Rolle. Seit wenigen Jahren wird der immunmodulatorische Therapieansatz intensiv in Studien untersucht. Daher soll dieser Artikel einerseits einen Überblick über die biologischen Mechanismen und die neuen immunotherapeutischen Substanzen geben und andererseits die aktuellen Studien sowie die etablierten Therapieverfahren darstellen.

Abstract

Advanced urothelial carcinoma of the bladder is an aggressive tumor with a poor prognosis. Besides surgical therapy, classical chemotherapy with platinum compounds is the mainstay of advanced bladder cancer treatment. In recent years, immune modulating therapies have come into the focus of clinical trials. This review provides an overview of the biological mechanisms and immuno-oncological drugs that are currently being analyzed in clinical trials as well as established standard therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Advanced Bladder Cancer (Abc) Meta-Analysis Collaboration (2005) Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur Urol 48:189–199 (discussion 199–201)

    Article  Google Scholar 

  2. Advanced Bladder Cancer (Abc) Meta-Analysis Collaboration (2005) Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol 48:202–205

    Article  Google Scholar 

  3. Bellmunt J, Theodore C, Demkov T et al (2009) Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 27:4454–4461

    Article  CAS  PubMed  Google Scholar 

  4. Hautmann RE, Gschwend JE, De Petriconi RC et al (2006) Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era. J Urol 176:486–492 (discussion 491–482)

    Article  PubMed  Google Scholar 

  5. Kitamura H, Tsukamoto T, Shibata T et al (2014) Randomised phase III study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer: japan clinical oncology group study JCOG0209. Ann Oncol 25:1192–1198

    Article  PubMed  Google Scholar 

  6. Leow JJ, Martin-Doyle W, Rajagopal PS et al (2014) Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials. Eur Urol 66:42–54

    Article  CAS  PubMed  Google Scholar 

  7. Motzer RJ, Escudier B, Mcdermott DF et al (2015) Nivolumab versus everolimus in advanced renal-cell carcinoma. New Engl J Med 373:1803–1813

    Article  CAS  PubMed  Google Scholar 

  8. Petrylak DP, Powles T, Bellmunt J et al (2015) A phase Ia study of MPDL3280A (anti-PDL1): Updated response and survival data in urothelial bladder cancer (UBC). J Clin Oncol 33(suppl). (abstr 4501)

  9. Plimack E, Bellmunt J, Gupta S et al (2015) Pembrolizumab (MK-3475) for advanced urothelial cancer: updated results and biomarker analysis from KEYNOTE-012. J Clin Oncol 33(suppl). (abstr 4502)

  10. Rosenberg J, Petrylak D, Abidoye O et al (2015) Atezolizumab in patients (pts) with locally-advanced or metastatic urothelial carcinoma (mUC): Results from a pivotal multicenter phase II study (IMvigor 210). In: ESMO/European Cancer Congress

  11. Sternberg CN, Skoneczna I, Kerst JM et al (2015) Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. Lancet Oncol 16:76–86

    Article  PubMed  Google Scholar 

  12. Powles TNJV, Fine GD, Eder JP, Braiteh FS, Loriot Y, Cruz Zambrano C, Bellmunt J, Burris HA, Teng S-LM, Shen X, Koeppen H, Hegde PS, Chen DS, Petrylak DP (2014) Inhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder cancer (UBC). J Clin Oncol 32(5s suppl). (abstr 5011)

  13. Von Der Maase H, Sengelov L, Roberts JT et al (2005) Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23:4602–4608

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Urologische Klinik und Poliklinik, Klinikum rechts der Isar der Technischen Universität München, München, Deutschland

    M. Retz, J. E. Gschwend &  S. C. Schmid

Authors
  1. M. Retz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. E. Gschwend
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. C. Schmid
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. C. Schmid.

Ethics declarations

Interessenkonflikt

Prof. Retz: Vortragsvergütungen und Honorare von Astellas Pharma GmbH, Janssen-Cilag GmbH, Pfizer GmbH, Bayer AG und GlaxoSmithKline GmbH & Co. KG. Prof. Gschwend: Vortragsvergütungen und Honorare von Astellas Pharma GmbH, Janssen-Cilag GmbH, Pfizer GmbH, Bayer AG, Amgen GmbH, Novartis AG, Roche GmbH, und GlaxoSmithKline GmbH & Co. KG. Dr. Schmid: Vortragsvergütungen von Astellas Pharma GmbH und Reiseunterstützung von GlaxoSmithKline GmbH &Co. KG und Bristol-Myers Squibb.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Retz, M., Gschwend, J.E. & Schmid, S.C. Update 2016 – Immuntherapie beim Urothelkarzinom. Urologe 55, 246–252 (2016). https://doi.org/10.1007/s00120-015-0024-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00120-015-0024-y

Schlüsselwörter

Keywords

Search

Navigation